Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 11.40 MB
Add to list
  1. Search results
  2. Probiotic potency of butyrate-produci...

Probiotic potency of butyrate-producing bacteria for modulating the microbiome and epithelial barrier in inflammatory bowel disease

Annelies Geirnaert (UGent)
(2015)
Author
Promoter
(UGent) and (UGent)
Organization
Abstract
Inflammatory bowel diseases (IBD) are characterized by a severe chronic, relapsing intestinal inflammation. An imbalance in structural and functional properties of the gut microbiota that can disrupt host-microbe homeostasis – defined as microbial dysbiosis – is associated with the etiology of IBD. Modulation of the dysbiosed gut microbiota in IBD is gaining more attention as a novel strategy to control the disease and to support current therapy. Butyrate-producing bacteria are considered as the future probiotics for IBD because butyrate has anti-inflammatory functions and has the capacity to strengthen the intestinal barrier. Before setting up clinical trials in humans with these novel probiotic candidates, more knowledge of their behavior under gastrointestinal conditions is required. The aim of this PhD research was to characterize and evaluate the potency of butyrate-producing bacteria, and especially of Butyricicoccus pullicaecorum, to modulate the microbiome and epithelial barrier in IBD. By using an in vitro intestinal technology platform, simulating the conditions from the stomach to the colon, we provided more insights in the potential of applying B. pullicaecorum or a mix of butyrate-producing bacteria as future probiotic for IBD.
Keywords
anaerobic bacteria, microbial therapy, Caco-2, gut flora, Crohn's disease, SHIME

Downloads

  • Download
    PhD AnneliesGeirnaert 2015 finalforpublication.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 11.40 MB

Citation

Please use this url to cite or link to this publication:

MLA
Geirnaert, Annelies. Probiotic Potency of Butyrate-Producing Bacteria for Modulating the Microbiome and Epithelial Barrier in Inflammatory Bowel Disease. Ghent University. Faculty of Bioscience Engineering, 2015.
APA
Geirnaert, A. (2015). Probiotic potency of butyrate-producing bacteria for modulating the microbiome and epithelial barrier in inflammatory bowel disease. Ghent University. Faculty of Bioscience Engineering, Ghent, Belgium.
Chicago author-date
Geirnaert, Annelies. 2015. “Probiotic Potency of Butyrate-Producing Bacteria for Modulating the Microbiome and Epithelial Barrier in Inflammatory Bowel Disease.” Ghent, Belgium: Ghent University. Faculty of Bioscience Engineering.
Chicago author-date (all authors)
Geirnaert, Annelies. 2015. “Probiotic Potency of Butyrate-Producing Bacteria for Modulating the Microbiome and Epithelial Barrier in Inflammatory Bowel Disease.” Ghent, Belgium: Ghent University. Faculty of Bioscience Engineering.
Vancouver
1.
Geirnaert A. Probiotic potency of butyrate-producing bacteria for modulating the microbiome and epithelial barrier in inflammatory bowel disease. [Ghent, Belgium]: Ghent University. Faculty of Bioscience Engineering; 2015.
IEEE
[1]
A. Geirnaert, “Probiotic potency of butyrate-producing bacteria for modulating the microbiome and epithelial barrier in inflammatory bowel disease,” Ghent University. Faculty of Bioscience Engineering, Ghent, Belgium, 2015.
@phdthesis{6942573,
  abstract     = {{Inflammatory bowel diseases (IBD) are characterized by a severe chronic, relapsing intestinal inflammation. An imbalance in structural and functional properties of the gut microbiota that can disrupt host-microbe homeostasis – defined as microbial dysbiosis – is associated with the etiology of IBD. Modulation of the dysbiosed gut microbiota in IBD is gaining more attention as a novel strategy to control the disease and to support current therapy. Butyrate-producing bacteria are considered as the future probiotics for IBD because butyrate has anti-inflammatory functions and has the capacity to strengthen the intestinal barrier. Before setting up clinical trials in humans with these novel probiotic candidates, more knowledge of their behavior under gastrointestinal conditions is required. 
The aim of this PhD research was to characterize and evaluate the potency of butyrate-producing bacteria, and especially of Butyricicoccus pullicaecorum, to modulate the microbiome and epithelial barrier in IBD. By using an in vitro intestinal technology platform, simulating the conditions from the stomach to the colon, we provided more insights in the potential of applying B. pullicaecorum or a mix of butyrate-producing bacteria as future probiotic for IBD.}},
  author       = {{Geirnaert, Annelies}},
  isbn         = {{9789059898295}},
  keywords     = {{anaerobic bacteria,microbial therapy,Caco-2,gut flora,Crohn's disease,SHIME}},
  language     = {{eng}},
  pages        = {{V, 165}},
  publisher    = {{Ghent University. Faculty of Bioscience Engineering}},
  school       = {{Ghent University}},
  title        = {{Probiotic potency of butyrate-producing bacteria for modulating the microbiome and epithelial barrier in inflammatory bowel disease}},
  year         = {{2015}},
}